These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24247820)

  • 21. MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment.
    Yarahmadi A; Shahrokhi SZ; Mostafavi-Pour Z; Azarpira N
    Biochem Pharmacol; 2021 Jul; 189():114301. PubMed ID: 33203517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNAs in kidney physiology and disease.
    Trionfini P; Benigni A; Remuzzi G
    Nat Rev Nephrol; 2015 Jan; 11(1):23-33. PubMed ID: 25385286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy.
    Batlle D; Soler MJ; Wysocki J
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):250-7. PubMed ID: 18408475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Novel biomarkers for diabetic nephropathy].
    Araki S
    Rinsho Byori; 2014 Feb; 62(2):171-9. PubMed ID: 24800493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of diabetic nephropathy--old buddies and newcomers part 1.
    Nawroth PP; Isermann B
    Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):571-6. PubMed ID: 20658438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy.
    Simpson K; Wonnacott A; Fraser DJ; Bowen T
    Curr Diab Rep; 2016 Mar; 16(3):35. PubMed ID: 26973290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetic nephropathy in humans: pathologic diversity.
    Valk EJ; Bruijn JA; Bajema IM
    Curr Opin Nephrol Hypertens; 2011 May; 20(3):285-9. PubMed ID: 21422920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic determinants of diabetic nephropathy.
    Chowdhury TA; Dyer PH; Kumar S; Barnett AH; Bain SC
    Clin Sci (Lond); 1999 Mar; 96(3):221-30. PubMed ID: 10029557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emerging role of angiotensin-converting enzyme-2 in the kidney.
    Burns KD
    Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):116-21. PubMed ID: 17293686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of renal renin-angiotensin system in mouse diabetic nephropathy.
    Tamura J; Konno A; Hashimoto Y; Kon Y
    Jpn J Vet Res; 2005 Aug; 53(1-2):13-26. PubMed ID: 16190318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy.
    Casagrande V; Federici M; Menghini R
    Acta Diabetol; 2021 Dec; 58(12):1587-1594. PubMed ID: 34181080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.
    Blumenthal SS
    Postgrad Med; 2011 Nov; 123(6):166-79. PubMed ID: 22104465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic determinants of diabetic renal disease and their impact on therapeutic interventions.
    Schmidt S; Ritz E
    Kidney Int Suppl; 1997 Dec; 63():S27-31. PubMed ID: 9407416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA biomarkers in clinical renal disease: from diabetic nephropathy renal transplantation and beyond.
    Nassirpour R; Raj D; Townsend R; Argyropoulos C
    Food Chem Toxicol; 2016 Dec; 98(Pt A):73-88. PubMed ID: 26925770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice.
    Wang J; Gao Y; Ma M; Li M; Zou D; Yang J; Zhu Z; Zhao X
    Cell Biochem Biophys; 2013 Nov; 67(2):537-46. PubMed ID: 23443810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring.
    Rossing K
    Dan Med Bull; 2007 May; 54(2):79-98. PubMed ID: 17521525
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of circular RNA in Diabetic Nephropathy.
    Tu C; Wang L; Wei L; Jiang Z
    Int J Med Sci; 2022; 19(5):916-923. PubMed ID: 35693742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid accumulation is ahead of epithelial-to-mesenchymal transition and therapeutic intervention by acetyl-CoA carboxylase 2 silence in diabetic nephropathy.
    Xu Y; Huang J; Xin W; Chen L; Zhao X; Lv Z; Liu Y; Wan Q
    Metabolism; 2014 May; 63(5):716-26. PubMed ID: 24650564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA in diabetic nephropathy: renin angiotensin, aGE/RAGE, and oxidative stress pathway.
    Hagiwara S; McClelland A; Kantharidis P
    J Diabetes Res; 2013; 2013():173783. PubMed ID: 24575418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.